VivoSeq
Cardiovascular

Diastolic Heart Failure

28

Pipeline Programs↗

0

Active Trials↗

16

Companies Involved↗

Diastolic Heart Failure is an emerging landscape with 28 programs across 16 companies. The most active players are Synvista Therapeutics, Inc, Amgen, Menarini International Operations Luxembourg SA. 11 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

11/100

Completion Rate

57/100

Attrition Rate

41/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Synvista Therapeutics, Inc

2 programs

Phase 2Amgen logo

Amgen

1 program

Phase 2M

Menarini International Operations Luxembourg SA

1 program

Phase 2M

Mezzion Pharma Co. Ltd

1 program

Phase 3V

Viatris Specialty LLC

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

27 of 30 classified programs — the dominant modality here.

10%ALL OTHERSPeptide310%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 100% of 31 pipeline programs.

Analysis

Trial Status

29

clinical trials

Completed16 · 55%
Terminated10 · 34%
Withdrawn2 · 7%
Unknown status1 · 3%

Clinical Trials

Trial Activity

29 trials

The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure
Completed·SSynvista Therapeutics, Inc·Phase 2·NCT00043836·20 enrolled
Physiological Effects of Grape Seed Extract in Diastolic Heart Failure
Completed·UUniversity of Michigan·Phase 1·NCT01185067·15 enrolled
Novel Treatment for Diastolic Heart Failure in Women
Completed·—·Phase 4·NCT00206232·48 enrolled
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure
Completed·WWake Forest University·Phase 3·NCT01411735·71 enrolled
The Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart Failure
Completed·SSt Vincent's University Hospital, Ireland·N/A·NCT00505336·43 enrolled
Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension
Completed·—·Phase 3·NCT00820352·20 enrolled
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Completed·—·Phase 3·NCT00763867·216 enrolled
Aldosterone Antagonism in Diastolic Heart Failure
Completed·US Department of Veterans Affairs·Phase 4·NCT00108251·48 enrolled
A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure
Completed·Pfizer logoPfizer·Phase 2·NCT00303498·200 enrolled
Ranolazine in Diastolic Heart Failure
Completed·Gilead logoGilead·Phase 2·NCT01163734·20 enrolled
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
Completed·UUniversity of Kansas Medical Center·Phase 2·NCT03133793·216 enrolled
A Trial of Fimasartan for Early Diastolic Heart Failure
Completed·—·Phase 4·NCT01691118·60 enrolled
Catheterization Laboratory Study: Acute Responses in Diastolic Heart Failure
Completed·UUniversity of Wisconsin, Madison·N/A·NCT00204945·15 enrolled
Study of Nesiritide in Diastolic Heart Failure.
Completed·MMassachusetts General Hospital·Phase 1/2·NCT00309868·20 enrolled
Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure
Completed·UUniversity of Milan·Phase 2/3·NCT01156636·44 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)